Skye Bioscience, Inc.
SKYE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001516551
In the last 90 days, Skye Bioscience, Inc. insiders filed 0 open-market purchases and 3 sales; 42 institutions reported holding it in 13F filings for Q2 2026, worth $11.1M in total; no superinvestor holds it.
Holders of 5% or more of SKYE
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Skye Bioscience, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| 5AM Partners VII, LLC | 13D/A | 26.10%1.22M shares | −4.10 ppfrom 30.20% | Aug 28, 20237 filings | Sep 24, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
22 Schedule 13D and 13G filings on Skye Bioscience, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Sep 24, 20264:30 PM ET | 5AM Partners VII, LLCand 8 others | 13D/A | 26.10%1.22M shares | −4.10 ppfrom 30.20% | Sep 22, 2026 | SEC |
| Aug 18, 20267:57 PM ET | 5AM Partners VII, LLCand 8 others | 13D/A | 30.20%11.3M shares | −3.80 ppfrom 34.00% | Aug 14, 2026 | SEC |
| Dec 16, 20254:30 PM ET | 5AM Partners VII, LLCand 8 others | 13D/A | 34.00%11.5M shares | −2.40 ppfrom 36.40% | Dec 12, 2025 | SEC |
| Aug 14, 20254:31 PM ET | Schonfeld Strategic Advisors LLC | 13G/A | 3.60%1.12M shares | −1.62 ppfrom 5.22%Below 5% | Jun 30, 2025 | SEC |
| May 15, 20254:31 PM ET | Schonfeld Strategic Advisors LLC | 13G | 5.22%1.62M shares | New | Mar 31, 2025 | SEC |
| Apr 10, 20255:27 PM ET | Sphera Funds Management Ltd.and 2 others | 13G/A | 4.77%1.48M shares | –Below 5% | Mar 31, 2025 | SEC |
| Dec 19, 20246:09 PM ET | 5AM Partners VII, LLCand 8 others | 13D/A | 36.40%11.7M shares | – | Dec 17, 2024 | SEC |
| Nov 14, 2024 | Altium Capital Management LP | 13G/AOld format | – | – | – | SEC |
| Nov 14, 2024 | Janus Henderson Group PLC | 13G/AOld format | – | – | – | SEC |
| Aug 14, 2024 | Janus Henderson Group PLC | 13GOld format | – | New | – | SEC |
| Mar 13, 2024 | 5AM Partners VII, LLC | 13D/AOld format | – | – | – | SEC |
| Feb 8, 2024 | Sphera Funds Management Ltd. | 13GOld format | – | New | – | SEC |
| Feb 5, 2024 | Altium Capital Management LP | 13GOld format | – | New | – | SEC |
| Jan 31, 2024 | 5AM Partners VII, LLC | 13D/AOld format | – | – | – | SEC |
| Aug 28, 2023 | Versant Venture Capital III, L.P. | 13GOld format | – | New | – | SEC |
| Aug 28, 2023 | 5AM Partners VII, LLC | 13DOld format | – | New | – | SEC |
| Mar 20, 2023 | Emerald Health Sciences Inc. | 13D/AOld format | – | – | – | SEC |
| Jan 31, 2022 | Emerald Health Sciences Inc. | 13D/AOld format | – | – | – | SEC |
| Jan 5, 2022 | Sabby Management, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Armistice Capital, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 5, 2021 | Bigger Capital Fund L P | 13G/AOld format | – | – | – | SEC |
| Jan 7, 2021 | Sabby Management, LLC | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
4 notices from officers, directors and other affiliates planning to sell Skye Bioscience, Inc. shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Nov 15, 20245:31 PM ET | Arsenault KaitlynOfficer | 57.1K | $314.5K | Nov 15, 2024 | Piper Sandler & Co Inc | SEC |
| Nov 15, 20245:28 PM ET | Dhillon PunitOfficer · Director | 100.7K | $554.8K | Nov 15, 2024 | Piper Sandler & Co Inc | SEC |
| Nov 15, 20245:25 PM ET | Diep Tuan TuOfficer | 22.9K | $126.1K | Nov 15, 2024 | Piper Sandler & Co Inc | SEC |
| Nov 15, 20245:22 PM ET | Grayson Paul A.Director | 86.8K | $478.3K | Nov 15, 2024 | Piper Sandler & Co Inc | SEC |